Christine Lovly
#162,740
Most Influential Person Now
American oncologist
Christine Lovly's AcademicInfluence.com Rankings
Christine Lovlymedical Degrees
Medical
#3520
World Rank
#3991
Historical Rank
Oncology
#248
World Rank
#256
Historical Rank
Download Badge
Medical
Christine Lovly's Degrees
- Masters Medicine University of Pennsylvania
- PhD Cancer Biology University of Pennsylvania
Why Is Christine Lovly Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christine M. Lovly is an associate professor of medicine at Vanderbilt University. Her research involves the development of novel treatment strategies for ALK positive lung cancer. Early life and education Lovly realised that she wanted to help people suffering from cancer at the age of sixteen. She studied chemistry at Johns Hopkins University. She moved to Washington University in St. Louis for her graduate studies, where she joined the Medical Scientist Training Program. She earned an MD–PhD in 2006. Lovly trained in internal medicine and medical oncology at Vanderbilt University and completed her residency in 2008. She was board certified in 2012 by the American Board of Internal Medicine.
Christine Lovly's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ROS1 rearrangements define a unique molecular class of lung cancers. (2012) (617)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. (2021) (423)
- Mechanisms of receptor tyrosine kinase activation in cancer (2018) (419)
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade (2016) (370)
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (2018) (354)
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy (2016) (352)
- Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. (2014) (304)
- Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. (2016) (261)
- Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer (2014) (237)
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants (2012) (236)
- Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids (2014) (230)
- Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding (2001) (221)
- RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer (2015) (219)
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine (2015) (216)
- Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. (2013) (212)
- Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies (2014) (207)
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. (2018) (206)
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors (2016) (202)
- Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. (2011) (197)
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials (2012) (188)
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors (2011) (183)
- Fragments of ATM which have dominant-negative or complementing activity (1997) (167)
- Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. (2003) (166)
- Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (147)
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies (2015) (143)
- Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade (2015) (127)
- Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (126)
- Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study (2018) (109)
- MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking (2014) (108)
- Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. (2019) (104)
- Quantifying Drug Combination Synergy along Potency and Efficacy Axes. (2019) (104)
- The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas (2006) (103)
- Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance (2012) (101)
- Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. (2014) (100)
- EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. (2015) (92)
- EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. (2016) (89)
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center (2015) (88)
- Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas (2015) (85)
- Longitudinal Cell‐Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse (2018) (83)
- SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. (2017) (80)
- Translating genomic information into clinical medicine: Lung cancer as a paradigm (2012) (79)
- EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. (2016) (78)
- Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (2014) (72)
- An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. (2017) (71)
- Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. (2017) (65)
- On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation (2019) (65)
- ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties (2018) (65)
- Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors (2015) (64)
- New approaches to small cell lung cancer therapy : from the laboratory to the clinic. (2020) (60)
- Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies (2014) (59)
- Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. (2017) (57)
- The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. (2006) (55)
- Lung cancer in 2010: One size does not fit all (2011) (52)
- COVID-19 and immune checkpoint inhibitors: initial considerations (2020) (49)
- A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. (2014) (47)
- Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. (2016) (41)
- Regulation of Chk2 Ubiquitination and Signaling through Autophosphorylation of Serine 379 (2008) (38)
- Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. (2017) (38)
- Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. (2006) (36)
- YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics (2018) (35)
- Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer (2014) (30)
- The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome12 (2016) (27)
- Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. (2022) (27)
- New Approaches to SCLC Therapy: From the Laboratory to the Clinic (2020) (27)
- Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes. (2019) (27)
- Guiding Oncology Patients Through the Maze of Precision Medicine (2016) (26)
- BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy (2018) (26)
- Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases. (2019) (25)
- Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting (2021) (23)
- Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer. (2021) (21)
- Tumor Heterogeneity and Therapeutic Resistance. (2016) (21)
- Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer (2015) (20)
- NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). (2013) (19)
- My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information (2016) (17)
- Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors (2015) (17)
- Managing Resistance to EFGR- and ALK-Targeted Therapies. (2017) (16)
- NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. (2014) (16)
- Established, emerging and elusive molecular targets in the treatment of lung cancer (2018) (16)
- Severity of illness scores at presentation predict ICU admission and mortality in COVID-19 (2021) (15)
- Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. (2016) (15)
- Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer (2021) (15)
- Non – Small Cell Lung Cancer, Version 3.2022 (2022) (15)
- Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC). (2017) (14)
- Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. (2018) (14)
- Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. (2015) (13)
- Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. (2016) (13)
- A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. (2014) (13)
- Major milestones in translational oncology (2016) (13)
- Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. (2015) (13)
- Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry. (2007) (13)
- Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC (2012) (12)
- The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA (2019) (12)
- DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment-A catalogue of clinically relevant somatic mutations in lung cancer. (2011) (11)
- Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer (2020) (11)
- Cancer Therapy : Preclinical See commentary by Crystal and Shaw , p . 4479 Differential Protein Stability and ALK Inhibitor Sensitivity of EML 4-ALK Fusion Variants (2012) (10)
- Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling. (2016) (10)
- MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X‐396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology (2016) (10)
- Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. (2022) (10)
- Melanoma driver mutations and immune therapy (2016) (10)
- Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) (2016) (10)
- Cancer Hallmarks Define a Continuum of Plastic Cell States between Small Cell Lung Cancer Archetypes (2021) (10)
- Tumor Heterogeneity and Therapeutic Resistance. (2016) (10)
- My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment. (2011) (9)
- MAP 2 K 1 ( MEK 1 ) Mutations De fi ne a Distinct Subset of Lung Adenocarcinoma Associated with Smoking (2015) (9)
- IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells (2022) (7)
- Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition (2020) (7)
- Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). (2016) (7)
- Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition (2019) (7)
- Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease (2020) (7)
- Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived. (2018) (7)
- YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. (2017) (6)
- Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance (2020) (6)
- A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. (2020) (6)
- Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC (2021) (6)
- P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK (2016) (6)
- A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors (2014) (6)
- APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. (2022) (5)
- Framework for Implementing and Tracking A Molecular Tumor Board at an NCI-Designated Comprehensive Cancer Center. (2021) (5)
- Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute – Designated Comprehensive Cancer Center (2021) (5)
- Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer. (2021) (5)
- Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. (2019) (5)
- Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. (2020) (5)
- 1700OGenomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types (2017) (4)
- Potentially actionable kinase fusions in inflammatory myofibroblastic tumors. (2013) (4)
- P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. (2016) (4)
- Update on HER1-3 in advanced non-small-cell lung cancer. (2012) (4)
- A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study. (2021) (4)
- Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181). (2021) (3)
- Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting. (2021) (3)
- Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx) (2016) (3)
- Abstract 1788: Preclinical development of a selective, potent small molecule ALK inhibitor (2010) (3)
- Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. (2019) (3)
- Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) (2016) (3)
- Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer (2022) (3)
- Managing Resistance to EFGR- and ALK-Targeted Therapies. (2017) (2)
- Abstract 1095: Comprehensive pan-cancer analyses of RAS genomic diversity (2020) (2)
- Mechanisms of Osimertinib Resistance in EGFR Mutant Lung Cancer (2017) (2)
- N-[18F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer. (2020) (2)
- 1OComprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types (2017) (2)
- Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC (2020) (2)
- Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). (2019) (2)
- Therapeutics , Targets , and Chemical Biology Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors (2011) (2)
- Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer (2017) (2)
- YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics (2018) (1)
- Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). (2015) (1)
- YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs). (2020) (1)
- Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. (2019) (1)
- Abstract 497: Understanding oncogenic fusions: Lessons learned from inflammatory myofibroblastic tumor (2015) (1)
- A Tale of Two Histologies: Dissecting the Biology of Lineage Transformation in Lung Cancer. (2021) (1)
- Abstract 4761: Transcriptomic overview of EML4-ALK lung cancer cells resistant to ALK inhibitors highlights a vulnerability to CDK inhibitors (2019) (1)
- Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data (2018) (1)
- FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study (2021) (1)
- B16 The ROS1 Cancer Model Project: A Unique Patient-Driven Partnership to Accelerate Research (2020) (1)
- Expanding Horizons for Treatment of Early-Stage Lung Cancer. (2022) (1)
- Intramolecular Dimerization of EGFR Kinase Domain Duplication as a Novel Activation Mechanism (2017) (1)
- Abstract 4949: Longitudinal monitoring of cell-free DNA in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse (2017) (1)
- P3.02c-024 Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling: Topic: Targeted Therapy (2017) (1)
- Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. (2022) (1)
- Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation (2022) (1)
- Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors. (2011) (1)
- OA10.02 Oncogene-Driven Patient Groups: A New Era For Research Partnerships (2018) (1)
- PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. (2016) (1)
- Longitudinal monitoring of circulating tumor DNA and peripheral T cell repertoire in patients with small cell lung cancer. (2017) (1)
- Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. (2021) (1)
- My Cancer Genome: Coevolution of Precision Oncology and a Molecular Oncology Knowledgebase (2021) (1)
- Abstract 1638: Potent anticancer actions of the Hsp90 inhibitor STA-9090 in wild-type EGFR models of lung cancer (2011) (1)
- B39 Cancer and Palliative Care in Rural India (West Bengal): Experience of an NGO (0)
- Abstract 752: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas (2015) (0)
- Abstract 3160: Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models ofEGFR-mutant cancer (2017) (0)
- Tumors Harbor Multiple Potentially Actionable Kinase Fusions (2014) (0)
- Mechanisms of receptor tyrosine kinase activation in cancer (2018) (0)
- Clinical implications of cell free DNA concentration in patients with small cell lung cancer. (2018) (0)
- FP07.15 Real-world ALK Testing Trends and Patterns in Patients with Advanced NSCLC in the United States (2021) (0)
- Abstract 3173: Integrative structural models of oncogenic mutants within the trans- and juxta-membrane region of human epidermal growth factor receptors (HERs) (2023) (0)
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. (2023) (0)
- Beyond biomarker testing: Aligning the needs of oncologist and diagnostic companies to improve biomarker results reports for accurate clinical treatment selection. (2022) (0)
- Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities. (2023) (0)
- Oncogene Mutations in Non-Small Cell Lung Cancer Have Increased Progression Free Survival and Overall Survival (2020) (0)
- Lorlatinib in NSCLC: Robust Efficacy Seen. (2017) (0)
- Serine 379 Signaling through Autophosphorylation of Regulation of Chk2 Ubiquitination and (2014) (0)
- Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review (2023) (0)
- P2.01-04 NCI-NRG Oncology ALK PROTOCOL (NRG-LU003): A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients (2019) (0)
- SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors (2022) (0)
- A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. (2022) (0)
- Abstract 3862: Defining immune contexture in small cell lung cancer: Implications for immunotherapy (2020) (0)
- Abstract 1025: Clinical outcomes and differential tumor immune microenvironment in patients with small cell lung cancer and paraneoplastic syndromes (2018) (0)
- Abstract 931: Comprehensive analysis of 3,600 small cell lung cancer cases reveals rare genetic subtypes and multiple mechanisms of histological transformation (2023) (0)
- Abstract 930: On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation (2019) (0)
- Abstract 102: Clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS p.G12C-mutated metastatic non-small cell lung cancer (NSCLC) in the AACR Project GENIE database (2021) (0)
- Abstract 22: Toward automated design of mutant-selective tyrosine kinase inhibitors using dynamic pharmacophore mapping and machine learning (2020) (0)
- Abstract B20: Prolonged time to clearance of circulating-tumor DNA from patients with limited-stage small-cell lung cancer is associated with inferior progression-free and overall survival (2020) (0)
- Abstract PO-018: Hematology oncology COllaborative VIDeoconferencing (COVID) Learning Initiative: A multi-institutional trainee alliance to rapidly disseminate emerging SARS-CoV2 and cancer best practices (2020) (0)
- Evaluation of immune checkpoints in small cell lung cancer: implications for immunotherapy (2020) (0)
- P1.14-20 Tarloxotinib as a Novel Therapeutic Strategy for Oncogenic Alterations Across the ErbB Family of Receptors (2019) (0)
- Analyzing Phospho-signaling in Human Glioblastoma Cell Lines Using Ex Vivo Culture (2017) (0)
- 45. Molecular tumor board efforts at Vanderbilt-Ingram Cancer Center (2019) (0)
- EPHA2BlockadeOvercomesAcquired Resistance to EGFR Kinase Inhibitors in Lung Cancer (2016) (0)
- Abstract 2942: NRAS mutation as a predictor of response to immune-based therapies in patients with metastatic melanoma (2014) (0)
- Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (0)
- MA 15.06 ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung Cancer (2017) (0)
- Melanoma-specific MHC-II expression to predict response to α-PD-1 therapy. (2015) (0)
- Molecular Genetics of Mature T/NK Neoplasms (2010) (0)
- A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors (2012) (0)
- Abstract 956: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas (2014) (0)
- Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer (2014) (0)
- , Saeko Serine 379 Signaling through Autophosphorylation of Regulation of Chk 2 Ubiquitination and (2008) (0)
- Prognostic Implications of KRAS Mutation Status and KRAS Mutation Type in Patients With Advanced NSCLC Treated With Cytotoxic Chemotherapy (2014) (0)
- Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. (2017) (0)
- Abstract 867: EGFR kinase domain duplication (EGFR-KDD) is activated by asymmetric intra-molecular dimerization (2019) (0)
- Abstract 330: High-throughput drug screens in osimertinib-resistant NSCLC cell lines, using continuous high-content imaging, identify potential co-targets to overcome acquired resistance (2019) (0)
- YIA22-003: Quantifying Minimal Residual Disease in Patients With Small Cell Lung Cancer (2022) (0)
- B41 Translating Lung Cancer Research into Primary Care Provider Training: An Innovative Online Course (0)
- A 75-year-old man with progressive bronchioalveolar carcinoma. (2013) (0)
- B40 IGF-Binding Protein-Mediated Sensitization of EGFR-Mutant NSCLC Cells to Osimertinib by Cancer-Associated Fibroblast (2020) (0)
- Abstract 3366: A machine learning approach to determine the cellular origin of variants in liquid biopsies (2023) (0)
- Alignment, Segmentation and Neighborhood Analysis in Cyclic Immunohistochemistry Data Using CASSATT (2022) (0)
- Characteristics of NSCLCs harboring NRAS mutations. (2012) (0)
- Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers (2022) (0)
- EP16.03-019 Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma (2022) (0)
- P76.41 Detection of Diverse EGFR c-terminal Truncations (C-trunc) and Sensitivity to Tyrosine Kinase Inhibitors (TKIs) in the Clinic (2021) (0)
- Abstract 311: Novel role for MIG-6 in mediating TKI resistance inALK-rearranged lung cancer (2016) (0)
- Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells (2019) (0)
- Abstract 316: Parallel activation of MEK as a mechanism of resistance to ALK inhibitor therapy (2019) (0)
- Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer. (2023) (0)
- Abstract 2367: Identification of ALK alternative transcription initiation in BRAF-negative metastatic melanoma patients (2017) (0)
- Distributing genomic data for cancer discovery. (2015) (0)
- P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles (2019) (0)
- A novel patient-derived cell line originated at the time of crizotinib resistance displays a mesenchymal phenotype (2016) (0)
- Abstract 3375: Molecular subtyping of circulating tumor cells in patients with small cell lung cancer (2022) (0)
- P1.14-29 Disrupting the Paradigm: Partnering with Oncogene-Focused Patient Groups to Propel Research (2019) (0)
- Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C–mutated metastatic colorectal cancer in AACR Project GENIE. (2023) (0)
- Abstract 715: Circulating tumor DNA as a potential biomarker of radiographic tumor burden in small cell lung cancer (2020) (0)
- Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
- Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma (2015) (0)
- Investigating the Activation Mechanism Alteration of Receptor Tyrosine Kinase Mutants (2019) (0)
- P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants (2021) (0)
This paper list is powered by the following services:
Other Resources About Christine Lovly
What Schools Are Affiliated With Christine Lovly?
Christine Lovly is affiliated with the following schools:
